Highest-materiality recent filing
Zevra Q2 2026 net revenue $39.7M, up 53% YoY; MIPLYFFA drives growth
Net revenue $39.7M, including $30.2M from MIPLYFFA; up from $25.9M in Q2 2025.
Zevra Q1 2026 net revenue $36.2M (+78% YoY); net income $37.9M; cash $236.8M after debt repayment
MIPLYFFA net revenue $24.6M; total net revenue $36.2M vs $20.4M in Q1 2025.
Zevra sells SDX portfolio to Commave for $50M, settles lawsuit, repays $63M debt
Total purchase price $50M; $25M at signing, $20M within 10 business days, $5M after records delivery.
Zevra reports Q4 net revenue $34.1M, net income $12.2M; appoints Justin Renz as CFO
Q4 2025 net revenue $34.1M (+31% QoQ); net income $12.2M ($0.19 diluted EPS) vs. $(35.7)M loss in Q4 2024.
Zevra Therapeutics CFO R. LaDuane Clifton resigns effective Dec 31, 2025
CFO Clifton to depart Dec 31, 2025 to pursue other professional opportunities.
Zevra Q3 net loss narrows to $0.5M; revenue jumps to $26.1M on MIPLYFFA sales
Q3 net revenue $26.1M (vs $3.7M YoY), with MIPLYFFA contributing $22.4M.
Zevra Q2 net revenue $25.9M, net income $74.7M on PRV sale; adjusted net loss $3.2M
Product net revenue $21.8M (MIPLYFFA $21.5M, OLPRUVA $0.3M) vs $4.4M total revenue in Q2 2024.
Zevra Q1 net revenue $20.4M, PRV sale nets $148M; net loss narrows to $3.1M
Q1 2025 net revenue $20.4M (up from $3.4M YoY); MIPLYFFA contributed $17.1M, OLPRUVA $0.1M.
Zevra closes $150M sale of rare pediatric disease PRV, boosting cash to ~$217M
Closed sale of Rare Pediatric Disease Priority Review Voucher for $150M gross proceeds on April 1, 2025.
Zevra Therapeutics reports FY 2024 net loss of $105.5M; sells PRV for $150M, cash runway into 2029
FY 2024 net revenue $23.6M (record Q4 product revenue $10.2M from MIPLYFFA); net loss ($105.5M) vs ($46.0M) in 2023.
Zevra sells PRV for $150M cash; funds MIPLYFFA & OLPRUVA launches
Gross proceeds of $150M, payable in cash at closing; expected within 30-45 days.
Zevra Therapeutics Announces Departure of Chief Development Officer and Chief Scientific Officer
Christal Mickle, Chief Development Officer and Co-Founder, notified of departure effective Dec. 6, 2024.
Zevra launches MIPLYFFA for NPC; early adoption ahead of expectations
MIPLYFFA (arimoclomol) commercially available at Zevra's specialty pharmacy; first FDA-approved NPC treatment.
Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone
Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.
FDA approved MIPLYFFA (arimoclomol) for NPC in adult and pediatric patients 2 years+; first FDA-approved NPC treatment.
Zevra Q2 revenue falls to $4.4M, net loss $19.9M; FDA decision on arimoclomol by Sept 21
Net revenue $4.4M vs $8.5M YoY; net loss $19.9M ($0.48/share) vs $2.6M ($0.08/share) in Q2 2023.
Zevra Therapeutics prices $60M common stock offering at $6.50/share; net proceeds ~$56.1M
9,230,770 shares sold at $6.50; underwriters have 30-day option for 1,384,615 additional shares.
Revenue for Q2 2024 expected between $4.2M and $4.6M, down from $8.47M in Q2 2023 which included a $5.0M milestone payment from AZSTARYS license.
FDA panel votes 11-5 that Zevra's arimoclomol is effective for NPC; PDUFA date Sep 21
FDA GeMDAC voted 11 yes, 5 no that data support arimoclomol as effective for Niemann-Pick disease type C.
Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024
FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.
Zevra reports positive Phase 2 trial results for KP1077 in idiopathic hypersomnia
KP1077 well-tolerated at up to 320 mg/day; AEs similar to methylphenidate, mostly mild (insomnia, headache, anxiety).
Zevra Q1 net loss $16.6M; OLPRUVA launch with 4 patients, cash runway into 2026
Net loss of $16.6M ($0.40 loss per share) compared to $13.2M loss in Q1 2023.
Zevra Therapeutics closes $100M senior secured loan facility; repays prior debt
Secured $100M loan; $60M funded, $20M available later, $20M contingent on FDA approval of arimoclomol for Niemann-Pick disease Type C.
Zevra restates FY2021-22 financials due to warrant errors; FY2023 revenue $27.5M
Q4 2023 net revenue $13.2M (vs $2.2M); FY2023 net revenue $27.5M (vs $10.2M). Net loss FY2023 $46.0M.
Zevra reports positive Phase 2 top-line data for KP1077 in idiopathic hypersomnia
KP1077 showed clinically meaningful improvement in excessive daytime sleepiness on ESS, maintained through open-label and double-blind phases.
FDA extends arimoclomol review; new PDUFA date Sept 21, 2024
FDA extended review of arimoclomol NDA for Niemann-Pick disease type C; new PDUFA action date Sept 21, 2024 (was June 21, 2024).
Zevra completes Acer acquisition; pro forma net loss $59.5M for 9-mo 2023
Pro forma net loss of $59.5M for nine months ended Sep 30, 2023; $80.7M for FY 2022.
FDA accepts Zevra's NDA resubmission for arimoclomol (NPC); PDUFA date June 21, 2024
FDA deems resubmission a Class II complete response with 6-month review; PDUFA date June 21, 2024.
Zevra resubmits NDA for arimoclomol (NPC) to FDA on Dec 22, 2023
FDA acknowledgment letter and PDUFA date expected within 30 days.
Zevra completes Acer acquisition; issues stock, CVRs, and $6M registered direct offering
Acquisition of Acer closed Nov 17; Acer shareholders receive 0.1210 Zevra shares + one CVR per share.
Zevra Therapeutics Q3 net loss widens to $14M; arimoclomol NDA resubmission on track
Net revenue flat at $2.9M; net loss ($0.40/share) vs ($0.19) in prior year.
Zevra Therapeutics appoints Neil F. McFarlane as CEO effective Oct 10, 2023
Neil F. McFarlane named President and CEO, succeeding interim CEO Christal Mickle who remains Chief Development Officer.
Zevra Therapeutics to acquire Acer Therapeutics in stock-and-CVR merger
Acer stockholders receive 0.120 Zevra shares per share plus one CVR; Zevra to issue ~2.96M shares.
Zevra sets $10M AZSTARYS milestone for 2023; merger with Acer announced
Next AZSTARYS sales milestone is $10.0M; expected to be achieved in FY 2023 per current prescription trends.
Q2 revenue $8.5M, net loss $5.1M; arimoclomol NDA resubmission on track for Q4 2023
Net revenue $8.5M in Q2 2023 vs $1.3M YoY, driven by $5M AZSTARYS milestone and royalties.
Zevra Therapeutics CEO resigns; Q1 net loss widens to $11.8M, revenue $2.9M
CEO Richard W. Pascoe resigns effective June 1, 2023; Chief Development Officer Christal Mickle appointed interim CEO.
Zevra Therapeutics dissident slate wins board seats; three new directors elected
Mangless-nominated directors Bode, Calder, Watton elected; company nominees Pascoe, Posner, Tierney received 3.3M, 2.7M, and 2.5M for votes vs 14.2M, 14.8M, and 15.0M withheld.
On January 20, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Alvin Shih, M.D. to serve as a director of the Company, effective immediately.
Resignation of Joseph B. Saluri from B
appointed Neil F. McFarlane to serve as the Company’s President and Chief Executive Officer, effective October 10, 2023
Concurrently with his appointment as President and Chief Executive Officer, Mr. McFarlane was appointed to serve as a member of the Board.
succeeding Christal M.M. Mickle., the Company’s former interim President and Chief Executive Officer, in such role. Ms. Mickle will continue serving in her role as Chief Development Officer.
On August 7, 2023, Matthew R. Plooster, a member of the Board of the Company, resigned from such position, effectively immediately after the appointment of Mr. Anderson.
On August 7, 2023, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Thomas Anderson to serve as a director of the Company, effective immediately.
As previously reported, Richard W. Pascoe resigned as Zevra’s Chief Executive Officer, effective as of the Effective Date.
On May 13, 2023, Zevra’s Board of Directors (the “Board”) appointed Christal M.M. Mickle, Zevra’s Chief Development Officer, as Zevra’s interim President and Chief Executive Officer
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
On May 5, 2023, Richard W. Pascoe, the Chief Executive Officer of Zevra Therapeutics, Inc. (the “Company” or “Zevra”), resigned as the Company’s Chief Executive Officer, effective as of June 1, 2023.
on May 3, 2023, Matthew R. Plooster and Joseph B. Saluri, each a Class III director of the Company, notified the Company’s Board of Directors (the “Board”) that they do not intend to stand for re-election at the Company’s 2024 annual meeting of stockholders.
Max materiality 0.90 · Median 0.72 · Most common event other_material